Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Zylox-Tonbridge Medical Technology Co., Ltd.
歸創通橋醫療科技股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2190)

PROPOSED AMENDMENTS TO THE 2021 H SHARE AWARD AND TRUST SCHEME

References are made to the announcement of Zylox-Tonbridge Medical Technology Co., Ltd. (the "**Company**") dated August 30, 2021 and circular dated September 7, 2021 in relation to the adoption by the Company on September 23, 2021 of the 2021 H Share Award and Trust Scheme (the "**2021 H Share Scheme**"). Pursuant to the 2021 H Share Scheme, the Company will instruct the trustee to conduct on-market purchase of H shares of the Company (the "**H Shares**") using internal funds provided by the Company. Such H Shares will be used as the H Shares underlying the awards to be granted thereunder. As at the date of this announcement, the Company has no plans to make further grants.

On April 1, 2026, the board (the "**Board**") of directors (the "**Directors**") of the Company considered and approved the proposed amendments to the 2021 H Share Scheme (the "**Proposed Amendments to the 2021 H Share Scheme**"). Pursuant to the Proposed Amendments to the 2021 H Share Scheme, the Board resolved to:

(i) propose increasing the scheme limit of the 2021 H Share Scheme from 9,972,000 H Shares to 10% of the total number of issued shares (excluding any treasury shares) as at the date of approval at the Company's 2025 annual general meeting (being the date on which the updated scheme limit is approved). Such amendment is to expand the scale of incentives and further advance the objectives of the existing H Share Scheme, including (without limitation) attracting, motivating and retaining talent. The H Share Scheme limit represents the maximum number of H Shares that may be granted to eligible participants and that the trustee may purchase from time to time in the secondary market; and

(ii) propose extending the validity period of the 2021 H Share Scheme for a term of 10 years commencing on the date of approval at the 2025 annual general meeting of the Company.

The 2021 H Share Scheme constitutes a share scheme funded by existing shares under Chapter 17 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"). Therefore, pursuant to the Listing Rules, the amendments to the 2021 H Share Scheme are not subject to the approval of shareholders. However, pursuant to the Company's Articles of Association and the terms of the 2021 H Share Scheme, the Proposed Amendments to the 2021 H Share Scheme are subject to approval of shareholders at the general meeting of the Company.

A circular containing, among other things, further details of the Proposed Amendments to the 2021 H Share Scheme and information regarding the forthcoming annual general meeting will be made available to the Company's shareholders as soon as practicable.

By Order of the Board
Zylox-Tonbridge Medical Technology Co., Ltd.
Dr. Jonathon Zhong Zhao
Chairman and Executive Director

Hong Kong, April 1, 2026

As of the date of this announcement, the Board comprises Dr. Jonathon Zhong Zhao, Mr. Yang Xie and Dr. Zheng Li as executive Directors, Dr. Steven Dasong Wang and Mr. Dongfang Li as non-executive Directors, and Dr. Jian Ji, Ms. Yun Qiu and Dr. Xiang Qian as independent non-executive Directors.